Huangpu enterprise attempts to cure Menkes syndrome

Yunzhou Biotechnology (Guangzhou) recently cooperated with Lantu Biotech, which focuses on developing gene medicines, to attempt the first gene therapy for Menkes syndrome, a rare congenital disease that affects the metabolism of copper in the body.

Yunzhou Biotech is a high-quality biopharmaceutical enterprise cultivated in Guangzhou's Huangpu district. It has grown into the world's largest scientific research-grade gene carrier service provider.

In Huangpu district and the Guangzhou High-tech Industrial Development Zone, there are nearly 40,000 small and medium-sized enterprises like Yunzhou Biotech and more than 100 specialized and sophisticated enterprises.

The "big incubation" cluster effect of the Guangzhou High-tech Zone has become increasingly apparent. It is now becoming one of the most active areas for incubator development and construction in the country.

Huangpu district and the Guangzhou High-tech Industrial Development Zone have also launched a series of policies, focusing on solving the difficulties faced by SMEs in regard to talent, finance, and innovation.

The Guangzhou High-tech Industrial Development Zone provides one-stop policy services for enterprises, such as settlement investment, growth and expansion, R&D and innovation, and talent support. This cultivates and expands its "specialized and sophisticated" enterprise group.

A rendering of an R&D and production base of Yunzhou Biotech.

The science and technology enterprise accelerator park in Huangpu district.

Share - WeChat